2-[3-(2-Chloroethyl)-3-nitrosoureido]-1,3-propanediol (Сhlonisol) is a representative of a separate group of derivatives of the class of nitrosoalkylureas – alkylnitrosoureidopropanediols, which are characterized by high antitumor activity on a wide range of experimental tumors. Chlonisol LD50 in male mice for intravenous administration was 35 mg/kg, intraperitoneal – 39 mg/kg, in female mice – 34 mg/kg and 36 mg/kg, respectively. In rats of males with intraperitoneal administration, LD50 was 30 mg/kg, in rats of females – 32 mg/kg. The maximum tolerated dose in mice, rats, guinea pigs and rabbits was 20 mg/kg. The tolerated dose for dogs was a dose of 2 mg/kg. Myelo-depression was a dose-limiting side effect. Lethal and sublethal doses of Chlonisol caused aplasia of the bone marrow and lymphoid organs, damage to the mucous membrane of the gastrointestinal tract, and dystrophic changes in the myocardium, lungs, liver, kidneys, pancreas, and reproductive organs. In the late stages after intraperitoneal administration of sublethal doses of Chlonisol, chylothorax and chyloperitoneum were found in some rats.